trastuzumab deruxtecan
1 product
45 abstracts
1 target
Target
HER2Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).Org: Department of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan, Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan, Department of Oncology, Sagara Hospital, Kagoshima, Japan, Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.Org: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, Precision Medicine in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Fondazione Pascale, Naples, Italy, Sapienza University of Rome, Medical Oncology Department, Policlinico Umberto I, Roma, Italy,
Abstract
Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials.Org: The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, CT, BronxCare Health System, The Bronx, NY, Samaritan Medical Centre,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.Org: University of Hawaii Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center,
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.Org: Adelaide Cancer Center, ICON Cancer Care, Austin, TX, Adelaide Cancer Center, Brisbane, Australia,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).Org: Maria Skłodowska-Curie National Research Institute and Oncology Centre, Hôtel-Dieu de Québec, Clinical Hospital “RZHD-Medicine”, Chi Mei Medical Center,
Abstract
Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Mutational landscape of HER-2 low breast cancer.Org: University of California, San Francisco, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, University of California, Irvine Medical Center,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).Org: Hadassah Medical Moscow, Srinagarind Hospital, Chris O’Brien Lifehouse,
Abstract
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Quantum Leap Healthcare Collaborative,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.Org: Jagiellonian University Medical College Hospital, Kraków, N.N Blokhin National Medical Research Center of Oncology, Reinier de Graaf Gasthuis, Delft,
Abstract
HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors.Org: Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development,
Abstract
HER2 low hormone positive breast cancer: Unveiling the driver.Org: Medical Research Institute, University of Alexandria,
Abstract
Clinicopathological characteristics and outcomes of patients with HER2-low breast cancer: 6-year ambispective cohort study from India.Org: Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Kasturba Medical College, Udupi, Manipal University Kasturba Medical College Manipal,
Abstract
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan.Org: Miami Cancer Institute, Baptist Health South Florida, Guardian Research Network,
Abstract
Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis.Org: Catholic University of Pelotas, RS, Brazil, Pelotas, Brazil, Universidade Estadual do Centro Oeste (UNICENTRO), Guarapuava, Brazil, Federal University of Amazonas - UFAM, Manaus, Brazil, University of Brasilia, Brasilia, Brazil,
Abstract
Identifying mutations in ctDNA to predict antibody-drug conjugate response in breast cancer.Org: UT Southwestern Medical Center, Dallas, TX,
Abstract
CNS efficacy of trastuzumab deruxtecan in metastatic breast cancer: A single-institution, real-world analysis.Org: UC San Diego, UC San Diego Moores Cancer Center,
Abstract
Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status.Org: nference Inc., AstraZeneca LLC,
Abstract
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.Org: Fudan University Shanghai Cancer Center, China National Biotec Group, West China Hospital, Chengdu Origen Biotechnology, Department of Preventive Medicine,
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.Org: University of California Comprehensive Cancer Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX, UC Davis, Davis, CA, Masonic Cancer Center, Minneapolis, MN,
Abstract
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Shanghai Medical College, Fudan University,
Abstract
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.Org: Stanford Hospital & Clinics, Department of Management Science and Engineering, Stanford University School of Medicine, Department of Health Policy,
Abstract
Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.Org: The Fourth Hospital of Hebei Medical University, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, West China Hospital, Shuwen Biotech Co. Ltd.,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.Org: Memorial Sloan Kettering Cancer Center,
Abstract
HER2-low breast cancer brain metastases: Incidence and treatment implications.Org: University of Toronto, Sunnybrook Hospital, Toronto, ON, Canada, Sunnybrook Health Sciences Center, Department of Laboratory Medicine and Pathobiology,
Abstract
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.Org: Duke Cancer Institute, Dana-Farber Cancer Institute, The Oncology Institute of Hope and Innovation, Suzhou Zanrong Pharma,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.Org: mProbe Inc., Stanford University School of Medicine,
Abstract
Implementation of a streamlined prior authorization process to improve cancer care delivery.Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, Resolution Bioscience, Agilent,
Abstract
Clinicopathologic features of early stage HER2-low breast cancer.Org: Comprehensive Hematology-Oncology, St. Petersburg, FL,
Abstract
Prevalence of low HER2 expression in breast cancer patients: An Indian experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Surgical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital,
Abstract
Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer.Org: Daiichi Sankyo Inc., Certara Germany GmbH, Daiichi Sankyo Shinagawa R&D Center, Daiichi Sankyo Europe GmbH,
Abstract
Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.Org: Saint Mary's and Saint Clare's Hospital, New York Medical College - Saint Michael's Medical Center, Schulich School of Medicine and Dentistry, BronxCare Health System, Dr. V.R.K. Women’s Medical College,
Abstract
Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity.Org: Avera Cancer Institute, Sioux Falls, SD, Theralink Technologies Inc, George Mason University, Manassas, VA,